idexx laboratories inc. - IDXX

IDXX

Close Chg Chg %
725.93 -8.46 -1.17%

Closed Market

717.47

-8.46 (1.17%)

Volume: 526.34K

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Company Overview: idexx laboratories inc. - IDXX

IDXX Key Data

Open

$725.33

Day Range

714.17 - 732.03

52 Week Range

356.25 - 769.98

Market Cap

$57.97B

Shares Outstanding

79.85M

Public Float

78.97M

Beta

1.67

Rev. Per Employee

N/A

P/E Ratio

58.09

EPS

$12.71

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

627.60K

 

IDXX Performance

1 Week
 
-3.58%
 
1 Month
 
2.47%
 
3 Months
 
12.90%
 
1 Year
 
66.62%
 
5 Years
 
58.79%
 

IDXX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About idexx laboratories inc. - IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDXX At a Glance

IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092-2040
Phone 1-207-556-0300 Revenue 3.90B
Industry Medical Specialties Net Income 887.87M
Sector Health Technology 2024 Sales Growth 6.461%
Fiscal Year-end 12 / 2025 Employees 11,000
View SEC Filings

IDXX Valuation

P/E Current 58.085
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 38.764
Price to Sales Ratio 8.831
Price to Book Ratio 21.148
Price to Cash Flow Ratio 37.05
Enterprise Value to EBITDA 27.935
Enterprise Value to Sales 9.01
Total Debt to Enterprise Value 0.028

IDXX Efficiency

Revenue/Employee 354,318.545
Income Per Employee 80,715.182
Receivables Turnover 6.944
Total Asset Turnover 1.189

IDXX Liquidity

Current Ratio 1.253
Quick Ratio 0.896
Cash Ratio 0.27

IDXX Profitability

Gross Margin 60.885
Operating Margin 28.919
Pretax Margin 28.475
Net Margin 22.78
Return on Assets 27.097
Return on Equity 57.657
Return on Total Capital 34.383
Return on Invested Capital 40.821

IDXX Capital Structure

Total Debt to Total Equity 61.865
Total Debt to Total Capital 38.22
Total Debt to Total Assets 29.967
Long-Term Debt to Equity 34.327
Long-Term Debt to Total Capital 21.207
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Idexx Laboratories Inc. - IDXX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.22B 3.37B 3.66B 3.90B
Sales Growth
+18.79% +4.73% +8.72% +6.46%
Cost of Goods Sold (COGS) incl D&A
1.31B 1.39B 1.47B 1.52B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
104.60M 111.90M 114.91M 129.94M
Depreciation
92.50M 96.90M 101.11M 112.84M
Amortization of Intangibles
12.10M 15.00M 13.80M 17.10M
COGS Growth
+15.60% +5.71% +6.18% +3.39%
Gross Income
1.90B 1.98B 2.19B 2.37B
Gross Income Growth
+21.11% +4.05% +10.51% +8.53%
Gross Profit Margin
+59.14% +58.76% +59.72% +60.88%
2021 2022 2023 2024 5-year trend
SG&A Expense
954.77M 1.10B 1.09B 1.25B
Research & Development
161.01M 254.82M 190.95M 219.79M
Other SG&A
793.76M 849.55M 902.99M 1.03B
SGA Growth
+9.24% +15.67% -0.94% +13.89%
Other Operating Expense
- - (1.46M) (2.20M)
-
Unusual Expense
- 4.30M (2.80M) (1.60M)
EBIT after Unusual Expense
944.05M 879.23M 1.09B 1.13B
Non Operating Income/Expense
(8.79M) 23.40M 10.24M 17.18M
Non-Operating Interest Income
434.00K 1.06M 5.63M 12.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
32.61M 42.66M 41.58M 36.07M
Interest Expense Growth
-8.98% +30.82% -2.52% -13.25%
Gross Interest Expense
32.61M 42.66M 41.58M 36.07M
Interest Capitalized
- - - -
-
Pretax Income
902.65M 859.97M 1.06B 1.11B
Pretax Income Growth
+36.36% -4.73% +23.40% +4.59%
Pretax Margin
+28.07% +25.54% +28.99% +28.48%
Income Tax
157.81M 180.88M 216.13M 221.96M
Income Tax - Current - Domestic
131.96M 180.63M 231.64M 205.15M
Income Tax - Current - Foreign
29.29M 35.14M 32.80M 41.00M
Income Tax - Deferred - Domestic
(7.52M) (37.40M) (42.96M) (29.35M)
Income Tax - Deferred - Foreign
4.09M 2.52M (5.34M) 5.16M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
744.84M 679.09M 845.04M 887.87M
Minority Interest Expense
- - - (1.00K)
-
Net Income
744.85M 679.09M 845.04M 887.87M
Net Income Growth
+28.03% -8.83% +24.44% +5.07%
Net Margin Growth
+23.17% +20.17% +23.08% +22.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
744.85M 679.09M 845.04M 887.87M
Preferred Dividends
- - - -
-
Net Income Available to Common
744.85M 679.09M 845.04M 887.87M
EPS (Basic)
8.7423 8.1208 10.1731 10.7663
EPS (Basic) Growth
+28.24% -7.11% +25.27% +5.83%
Basic Shares Outstanding
85.20M 83.62M 83.07M 82.47M
EPS (Diluted)
8.6038 8.0271 10.0627 10.6656
EPS (Diluted) Growth
+28.25% -6.70% +25.36% +5.99%
Diluted Shares Outstanding
86.57M 84.60M 83.98M 83.25M
EBITDA
1.05B 988.33M 1.21B 1.26B
EBITDA Growth
+32.92% -6.14% +22.17% +4.11%
EBITDA Margin
+32.75% +29.35% +32.98% +32.25%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 779.50
Number of Ratings 17 Current Quarters Estimate 2.934
FY Report Date 12 / 2025 Current Year's Estimate 12.928
Last Quarter’s Earnings 3.40 Median PE on CY Estimate N/A
Year Ago Earnings 10.67 Next Fiscal Year Estimate 14.447
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 8 12 12
Mean Estimate 2.93 3.34 12.93 14.45
High Estimates 3.00 3.54 13.00 14.97
Low Estimate 2.87 2.94 12.86 14.18
Coefficient of Variance 1.36 5.38 0.30 1.41

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 8
OVERWEIGHT 2 2 1
HOLD 5 5 7
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Idexx Laboratories Inc. - IDXX

Date Name Shares Transaction Value
Aug 13, 2025 Jonathan J. Mazelsky President and CEO; Director 83,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $598.49 per share 49,970,324.06
Aug 13, 2025 Jonathan J. Mazelsky President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 11,606 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $206.94 per share 2,401,745.64
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 6,156 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $651.6 per share 4,011,249.60
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 6,339 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $544.08 per share 3,448,923.12
Feb 20, 2025 George J. Fennell Executive Vice President 112 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 303 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,820 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,512 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,209 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 417 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 816 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 3,415 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 8,347 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $444.53 per share 3,710,491.91
Feb 20, 2025 Michael P. Johnson Executive Vice President 535 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 8,340 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Idexx Laboratories Inc. in the News